Strata Oncology Expands Strata PATH Trial to Eight Sarah Cannon Research Institute Sites

Strata Oncology, Inc., a next-generation precision oncology company enabling smarter and earlier cancer treatment, today announced that Sarah Cannon Research Institute (SCRI) has joined the Strata Precision Indications for Approved THerapies (Strata PATH^™) trial.